Monday, 18 Jun 2018

You are here

Tofacitinib Effective in Ulcerative Colitis

Tofacitinib is currently approved for use in rheumatoid arthritis, but is being studied in numerous other inflammatory conditons including spondylitis, psoriasis, psoriatic arthritis, and has also been studied in patients with ulcerative colitis (UC).

The NEJM has reported the results of 3 randomized, double-blind, placebo-controlled trials of 10 mg bid tofacitinib therapy in adults with ulcerative colitis - these include the OCTAVE Induction 1 and 2 trials (598 and 541 patients) and the OCTAVE Sustain trial (593 patients) wherein those responding to induction therapy, receive maintenance therapy with tofacitinib (either 5 mg or 10 mg twice daily) or placebo for 52 weeks. The primary end point was remission at 52 weeks.

In OCTAVE 1, the induction trial, remission at 8 weeks was the primary endpoint that was achieved in 18.5% of tofacitinib (10 mg bid) patients versus 8.2% of those on placebo (P=0.007).

The OCTAVE Induction 2 trial, remission occurred in 16.6% versus 3.6% (P<0.001).

In the OCTAVE Sustain trial, those responding were re-randomized to either 5 mg or 10 mg bid tofacitinib or placebo and followed for 52 weeks.  Remission was seen in 34.3%, 40.6% and 11.1%  of thosed taking tofacitinib 5 mg, tofacitinib 10 mg and the placebo group respectively (P<0.001 for both tofa groups vs. placebo).

Serious adverse events and serious infections were not different between groups, but there were more episodes of herpez zoster and hyperlipidemia in those treated with tofacitinib.

These trials suggest the induction efficacy of tofacitinib but only at the 10 mg bid dose - a dose that has not yet been FDA approved in the US. 

Disclosures: 
The author has received research/grant financial support on this subject

Add new comment

More Like This

High Biologic Blood Levels Increases the Risk of Infections in RA

A big concern of most is the risk of infection with use of tumour necrosis factor inhibitor (TNFi) and biologic drugs.  While studied in both trials and in post-marketing studies, it is unknown if infection risk is dose-dependent.

In abstract OP0229 UK researchers have shown high biologic blood levels are associates with an increased risk of total infections in RA, but not serious infetions.

Biosimilar Data at #EULAR2018

Biosimilars are here, and more are being registered all the time, so I was really interested in the biosimilar data at the meeting.

Abbvie Highlights Upadacitinib Trials at EULAR18

Abbvie press releases feature the results from 3 new trials to be presented during the Annual European Congress of Rheumatology (EULAR 2018) in Amsterdam from three Phase 3 trials evaluating upadacitinib, an investigational, once-daily oral JAK1-selective inhibitor, in adult patients with moderate to severe rheumatoid arthritis.

Vedolizumab Implicated in Exacerbations of SpA in IBD Patients

Beloved by gastroenterologist for treatment of inflammatory bowel disease (IBD), α4β7 integrin receptor vedolizumab (VDZ) has probably caught attention of many rheumatologist since the time it entered the market; largely for what it won't do for inflammatory arthritis.

JAK Inhibition in Autoinflammatory Syndromes Interferonopathies

While many autoinflammatory syndromes are driven and managed with select inhibition of IL-1, IL-18 or IL-6, a subset are driven by type I interferon and are referred to as interferonopathies. These monogenic IFN–mediated disorders present in infancy with fevers, systemic inflammation, an IFN response gene signature, inflammatory organ damage, and high mortality.